

# PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease



Thomas Nyström, MD, PhD,<sup>a,b</sup> Ulrik Sartipy, MD, PhD,<sup>c,d</sup> Stefan Franzén, PhD,<sup>e</sup> Björn Eliasson, MD, PhD,<sup>e</sup> Soffia Gudbjörnsdóttir, MD, PhD,<sup>e</sup> Mervete Miftaraj, MSc,<sup>e</sup> Bo Lagerqvist, MD, PhD,<sup>f</sup> Ann-Marie Svensson, PhD,<sup>e</sup> Martin J. Holzmann, MD, PhD<sup>g,h</sup>

## JACC JOURNAL CME/MOC

This article has been selected as the month's *JACC* Journal CME/MOC activity, available online at <http://www.acc.org/jacc-journals-cme> by selecting the *JACC* Journals CME/MOC tab.

### Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME/MOC activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### Method of Participation and Receipt of CME/MOC Certificate

To obtain credit for *JACC* CME/MOC, you must:

1. Be an ACC member or *JACC* subscriber.
2. Carefully read the CME/MOC-designated article available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME/MOC credit.
4. Complete a brief evaluation.
5. Claim your CME/MOC credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

**CME/MOC Objective for This Article:** After reading this article, the reader should be able to: 1) compare type 1 diabetes and type 2 diabetes in terms

of prevalence, etiology, risk factors, age at onset of disease, proportion of men and women, socio-economy (length of education, disposable income), treatment, and risk of developing cardiovascular disease; 2) discuss what is known about prognosis in type 1 and type 2 diabetes patients undergoing multivessel revascularization, and if the current recommended strategy of revascularization in diabetes patients may be generalized to both type 1 and type 2 diabetes patients; and 3) identify and compare the importance of potential predictors of adverse outcome in patients with type 1 and type 2 diabetes and established coronary artery disease.

**CME/MOC Editor Disclosure:** *JACC* CME/MOC Editor Ragavendra R. Baliga, MD, FACC, has reported that he has no financial relationships or interests to disclose.

**Author Disclosures:** Dr. Holzmann holds a research position funded by the Swedish Heart-Lung Foundation (grant no. 20150603); and has received consultancy honoraria from Actelion and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**Medium of Participation:** Print (article only); online (article and quiz).

### CME/MOC Term of Approval

Issue Date: September 19, 2017

Expiration Date: September 18, 2018



Listen to this manuscript's audio summary by *JACC* Editor-in-Chief Dr. Valentin Fuster.



From the <sup>a</sup>Department of Clinical Sciences and Education, Karolinska Institutet, Stockholm, Sweden; <sup>b</sup>Division of Internal Medicine at Södersjukhuset, Stockholm, Sweden; <sup>c</sup>Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden; <sup>d</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; <sup>e</sup>Institute of Medicine, Sahlgrenska University Hospital, Centre of Registers in Region Västra Götaland, Göteborg, and University of Gothenburg, Göteborg, Sweden; <sup>f</sup>Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala; <sup>g</sup>Functional Area of Emergency Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden; and the <sup>h</sup>Department of Internal Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. Dr. Holzmann holds a research position funded by the Swedish Heart-Lung Foundation (grant no. 20150603); and has received consultancy honoraria from Actelion and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received June 22, 2017; revised manuscript received July 18, 2017, accepted July 21, 2017.

## PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease

Thomas Nyström, MD, PhD,<sup>a,b</sup> Ulrik Sartipy, MD, PhD,<sup>c,d</sup> Stefan Franzén, PhD,<sup>e</sup> Björn Eliasson, MD, PhD,<sup>e</sup> Soffia Gudbjörnsdóttir, MD, PhD,<sup>e</sup> Mervete Miftaraj, MSc,<sup>e</sup> Bo Lagerqvist, MD, PhD,<sup>f</sup> Ann-Marie Svensson, PhD,<sup>e</sup> Martin J. Holzmann, MD, PhD<sup>g,h</sup>

### ABSTRACT

**BACKGROUND** It is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization.

**OBJECTIVES** This study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI.

**METHODS** In an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores.

**RESULTS** In total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53% of patients in the CABG group and 45% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found.

**CONCLUSIONS** Notwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization. (J Am Coll Cardiol 2017;70:1441-51) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Among patients who undergo multivessel revascularization with coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI), 25% have diabetes. A mortality benefit favoring CABG over PCI has been proven for patients with diabetes. In the BARI (Bypass Angioplasty Revascularization Investigation) study, patients with diabetes who underwent PCI had almost double the 5-year mortality of those who underwent CABG (1). Later, the FREEDOM (Future REvascularization Evaluation in patients with Diabetes Mellitus) study, where 1,900 patients with diabetes and multivessel disease were randomized to undergo either PCI or CABG, demonstrated a reduction in the composite outcome of death from any cause, nonfatal myocardial infarction, or nonfatal

stroke in favor of CABG over PCI (2). Similarly, in a subgroup analysis of 452 patients with diabetes who were randomized to either PCI or CABG in the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) trial, a survival benefit was found for patients treated with CABG (3). For this reason, current guidelines support CABG over PCI as the preferred treatment of multivessel disease in patients with diabetes (4,5).

None of the abovementioned studies reported the proportion of patients with type 1 diabetes (T1D) included. However, type of diabetes may also be of great importance because the long-term prognosis after CABG is dire in patients with T1D (6), compared with patients with type 2 diabetes (T2D) whose long-term prognosis is similar to that of patients without

diabetes (3,6). The reason for the poor prognosis in patients with T1D after CABG is not fully understood; however, factors such as diabetes duration and glyce-mic control may be of great importance (7). Therefore, the recommendation that all diabetes patients in need of multivessel revascularization should undergo CABG cannot easily be translated to patients with T1D.

Thus, it is unknown whether patients with T1D have the same benefit as patients with T2D from CABG compared with PCI. Therefore, we performed a nationwide, population-based cohort study in all patients with T1D who underwent a first multivessel revascularization with either CABG or PCI over a period of 19 years in Sweden.

SEE PAGE 1452

## METHODS

**DATA SOURCES AND STUDY POPULATION.** The study database was created by using the unique personal identity number assigned to every Swedish resident as the identifier to crosslink a number of Swedish national health care registries. The records linkage procedure was performed at the Swedish National Board of Health and Welfare, which anonymized the database before it was returned to the research group.

All patients with T1D who underwent a first isolated multivessel (defined as involving at least 2 significantly stenosed coronary arteries) cardiac revascularization with PCI or isolated CABG from 1995 to 2013 in Sweden were included. Exclusion criteria were prior cardiothoracic surgery; prior or current left main coronary artery revascularization; emergency procedure; valvular heart surgery or vascular surgery concurrently with CABG, or PCI for ST-segment elevation myocardial infarction; prior single-vessel PCI in the PCI group; and T1D diagnosed after the index date. The study population was identified and baseline characteristics obtained from the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register (8) and the NDR (Swedish National Diabetes Register) register (9), and further expanded with information about comorbidities and outcomes from the National Patient Register (10), date and cause of death from the Cause-of-Death register, and socio-economic data from Statistics Sweden. Data sources are described in detail in the [Online Appendix](#). How data from different sources was retrieved is described in [Online Figure 1](#).

**DEFINITION OF T1D.** Data from all patients with T1D, according to either an epidemiological or clinical

definition, were obtained from the NDR register ([Online Appendix](#)). The epidemiological definition of T1D was onset of diabetes before the age of 30 years and treatment with insulin only (9). The clinical definition of T1D in the NDR register was decided at an outpatient visit, normally to an endocrinologist, and registered in the NDR register. The coverage of T1D patients in the NDR register is virtually complete for the whole country of Sweden (9).

**FOLLOW-UP AND OUTCOMES.** The primary outcome was all-cause mortality, and secondary outcomes were death from coronary heart disease, myocardial infarction, stroke, and repeat revascularization. Follow-up started when the first multivessel PCI or CABG was performed for all-cause mortality, and stroke. For repeat revascularization follow-up started at 8 days after revascularization, and for myocardial infarction, and heart failure 31 days after revascularization. Follow-up ended for all outcomes when the patient died, was hospitalized for each outcome, or on December 31, 2014. Data on rehospitalizations for myocardial infarction, heart failure, stroke, or repeat revascularization was obtained from the National Patient Register or the SWEDEHEART register. International Classification of Diseases codes for the outcome measures and comorbidities are shown in [Online Table 1](#).

**STATISTICAL ANALYSIS.** Missing baseline values were imputed using multiple chained equations imputation, as implemented in the MICE package in R, version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria), creating 10 imputed datasets. The percentage of missing values ranged from 61.1% for low-density lipoprotein to 0% for age, sex, and comorbidities ([Online Table 2](#)). The imputation worked well according to the convergence and distribution of the imputed variables. Observed and imputed values of missing data are shown in [Online Figure 2](#).

Descriptive statistics are presented in terms of averages and percentages, together with the standardized difference before weighting. Comparisons between CABG and PCI with respect to health outcomes were made using weighted Cox regressions where the weights were derived as the average weights from propensity scores estimated using gradient boosting. The balance before and after weighting for patient characteristics is shown in [Online Figure 3](#). The assumption of proportional hazards was evaluated by plotting the  $\log(\log[S(t)])$ , where  $S(t)$  is the estimated survival function. Although the assumption of proportional hazards was not exactly met, as it rarely is in practice, the hazard ratio (HR) was judged a reasonably

## ABBREVIATIONS AND ACRONYMS

**CABG** = coronary artery bypass grafting

**CI** = confidence interval

**HR** = hazard ratio

**PCI** = percutaneous coronary intervention

**T1D** = type 1 diabetes

**T2D** = type 2 diabetes

<b>TABLE 1 Characteristics of 2,546 Patients With Type 1 Diabetes Who Underwent Multivessel Revascularization From 1995-2013 in Sweden</b>			
	<b>CABG</b>	<b>PCI</b>	<b>Standardized Difference</b>
Patients	683 (27)	1,863 (73)	N/A
Time period of revascularization			
1995-2000	441 (58)	324 (42)	N/A
2001-2006	197 (21)	741 (79)	N/A
2007-2013	45 (5)	798 (95)	N/A
Age, yrs	57.2 ± 10.0	61.1 ± 10.5	0.378
Female	36.6	41.1	0.093
HbA <sub>1c</sub> , mmol/mol	68.8 ± 14.6	67.3 ± 13.4	0.111
Diabetes duration, yrs	29.6 ± 16.0	31.6 ± 16.8	0.122
Macroalbuminuria	24.1	22.4	0.040
Microalbuminuria	25.6	28.5	0.065
GFR, ml/min/1.73 m <sup>2</sup>	70 ± 23	67 ± 29	0.094
Current smoker	15.0	14.5	0.016
BMI, kg/m <sup>2</sup>	26.0 ± 3.9	26.4 ± 4.3	0.087
Systolic BP, mm Hg	142 ± 19	139 ± 18	0.141
Diastolic BP, mm Hg	75 ± 9	73 ± 10	0.152
Triglycerides, mg/dl	133 ± 80	133 ± 97	0.033
HDL cholesterol mg/dl	58 ± 23	58 ± 19	0.038
LDL cholesterol, mg/dl	104 ± 39	108 ± 39	0.163
MI			0.602
Acute MI, within 14 days	13.6	36.7	
Previous MI	54.3	47.6	
Comorbidities			
Previous stroke	6.6	9.6	0.111
Previous HF	16.3	19.5	0.086
Atrial fibrillation	7.0	6.0	0.043
COPD	2.9	3.3	0.023
Peripheral arterial disease	4.4	4.5	0.003
End-stage renal disease	3.2	7.0	0.179
Active cancer	1.5	3.9	0.149
Psychiatric disease	1.3	2.7	0.101
Education			0.126
<10 yrs	37.2	33.1	
10-12 yrs	42.5	44.8	
>12 yrs	17.0	16.7	
Income (Swedish krona)			0.289
Quartile 1	31	23	
Quartile 2	29	24	
Quartile 3	23	26	
Quartile 4	17	28	

Continued in the next column

fair summary of the effect of treatment as an average over time. To account for residual confounding, the models contained age, prior coronary heart disease, and index year.

Statistical hypothesis tests were evaluated using the 5% significance level without any adjustment for multiple comparisons. The analysis was implemented using R and SAS statistical analysis software, version 9.4 (SAS Institute Inc., Cary, North Carolina).

<b>TABLE 1 Continued</b>			
	<b>CABG</b>	<b>PCI</b>	<b>Standardized Difference</b>
Marital status			0.162
Married	63.4	55.8	
Other	36.6	44.2	
Birth region			0.076
Nordic countries	90.8	88.5	
Other	9.2	11.5	
Region			0.404
North	10.5	10.0	
Stockholm	13.3	20.3	
Southeast	7.2	11.1	
South	15.4	17.9	
Uppsala-Örebro	20.6	23.8	
West	32.9	17.0	


Values are n (%), mean ± SD, or %. Glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration formula. Macroalbuminuria was defined as >200 mg/L and microalbuminuria was defined as 20-200 ng/L. End-stage renal disease was defined as dialysis-dependent kidney disease, or need of kidney transplantation. Previous myocardial infarction (MI) means MI that occurred any time before the index date. Income is defined as yearly household disposable income. Region shows the proportion of all revascularizations during the whole study period that were performed in hospitals belonging to different regions of Sweden.

BMI = body mass index; BP = blood pressure; CABG = coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; HbA<sub>1c</sub> = glycated hemoglobin A1c; HDL = high-density lipoprotein; HF = heart failure; LDL = low-density lipoprotein; N/A = not applicable; PCI = percutaneous coronary intervention.

## RESULTS

**STUDY GROUP.** During the study period, 2,546 patients with T1D underwent a first multivessel revascularization, of which 73% underwent PCI. The selection of the study group is described in [Figure 1](#). Patients treated with PCI were older, more often women, had a longer duration of diabetes, and were more likely to have had previous myocardial infarctions and strokes ([Table 1](#)). Three-vessel disease was more common in the CABG group compared with the PCI group (84% vs. 58%). From 1995 to 1999, the predominant strategy for multivessel revascularization was CABG (62% vs. 38%). Thereafter, there was a steady decline in the proportion of CABG compared with PCI, with 2% CABG versus 98% PCI from 2010 to 2013 ([Table 1](#), [Online Table 3](#)).

**MORTALITY.** During a mean 10.6 ± 5.1 years (22,386 person-years) of follow-up, 44.6% patients in the PCI group and 53.3% in the CABG group died ([Table 2](#)). The absolute risk of death was higher at 1 year (5.0% vs. 0.7%), 2 years (8.3% vs. 1.2%), and 5 years (18.6% vs. 6.4%) after revascularization in patients who underwent PCI compared with CABG ([Table 3](#), [Central Illustration](#)). The rate of death per 100 person-years was higher in the PCI group than in the CABG group (6.0/100 person-years vs. 4.3/100 person-years).



The risk of death after adjustment for differences between groups was similar in the PCI group compared to the CABG group (HR: 1.14; 95% CI: 0.99 to 1.32). Cause-specific mortality showed that patients who underwent PCI were more likely to die from coronary heart disease than were patients who underwent CABG (HR: 1.45; 95% CI: 1.21 to 1.74) (Table 2, Figure 2A).

**MYOCARDIAL INFARCTION, HEART FAILURE, STROKE, AND REPEAT REVASCULARIZATION.** The absolute risks at 1 year, 2 years, and 5 years after revascularization for myocardial infarction, heart failure, stroke, and repeat revascularizations were consistently higher

in patients who underwent PCI compared with those who underwent CABG, with the largest difference found for repeat revascularizations (Table 3, Figures 2B to 2E). The rate and adjusted risk of myocardial infarction in the PCI group was higher than in the CABG group (4.6/100 person-years vs. 2.7/100 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77) (Table 2). Similarly, the adjusted risk for and the frequency of repeat revascularization was higher in the PCI group than in the CABG group (20.1/100 person-years vs. 1.9/100 person-years; adjusted HR: 5.64; 95% CI: 4.67 to 6.82). Repeat revascularization was performed using CABG in 64% of the cases in the PCI group, compared with 1%

**TABLE 2 Risk of Death, MI, HF, Stroke, and Repeat Revascularization in Patient With T1D Who Underwent Multivessel PCI or CABG in Sweden From 1995-2013**

Outcome	Number of Events (%)	Person-Yrs of Follow-Up	Event Rate/100 Person-Yrs	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
<b>Death</b>					
CABG	364 of 683 (53.3)	8,564	4.3	Referent	Referent
PCI	831 of 1,863 (44.6)	13,823	6.0	1.86 (1.64-2.11)	1.14 (0.99-1.32)
<b>MI</b>					
CABG	224 of 683 (34.1)	8,315	2.7	Referent	Referent
PCI	502 of 1,863 (33.5)	11,006	4.6	1.67 (1.42-1.96)	1.47 (1.23-1.78)
<b>HF</b>					
CABG	251 of 683 (39.1)	7,765	3.2	Referent	Referent
PCI	561 of 1,863 (33.0)	12,257	4.6	1.41 (1.21-1.64)	1.10 (0.91-1.32)
<b>Stroke</b>					
CABG	127 of 683 (18.6)	9,072	1.4	Referent	Referent
PCI	237 of 1,863 (12.7)	15,489	1.5	1.00 (0.80-1.25)	1.00 (0.76-1.31)
<b>Repeat revascularization</b>					
CABG	166 of 683 (24.3)	8,821	1.9	Referent	Referent
PCI	1,222 of 1,863 (65.6)	6,089	20.1	5.65 (4.78-6.68)	5.64 (4.67-6.82)
<b>Death from CHD</b>					
CABG	190 of 683 (27.8)	9,203	2.1	Referent	Referent
PCI	430 of 1,863 (23.1)	15,020	2.9	1.63 (1.37-1.94)	1.45 (1.21-1.74)

Follow-up started at the time of revascularization for death, stroke, and death from coronary heart disease. For MI and heart failure (HF), follow-up started 31 days after revascularization, and follow-up for repeat revascularization started 8 days after revascularization.  
CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; T1D = type 1 diabetes; other abbreviations as in Table 1.

in the CABG group. The 30-day rate of stroke was higher in the CABG group than in the PCI group (1.9% vs. 0.8%), but there was no difference in the long-term adjusted risk of stroke between the PCI and CABG groups. The adjusted risk of hospitalization for heart failure was similar in the PCI and CABG groups.

## DISCUSSION

In this nationwide cohort study including all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013, we found a benefit favoring CABG over PCI, with lower rates and

risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization, with no such differences found for all-cause mortality, stroke, and heart failure.


Earlier studies have provided evidence of a benefit for CABG compared with PCI in terms of prognosis in patients with diabetes in need of multivessel revascularization (1-3,11). The strongest evidence for using CABG over PCI as the preferred strategy for multivessel revascularization in patients with diabetes comes from the FREEDOM study (2); however, none of the previously mentioned studies reported the proportion of included T1D compared with T2D patients. Because 85% to 90% of all patients with diabetes have T2D (12), it is likely that the proportion of T1D patients included was very small. To the best of our knowledge, only 1 previous study that compared PCI with CABG for multivessel revascularization in patients with diabetes sorted patients into T1D and T2D subgroups (13). This study was prematurely stopped due to slow enrollment, comprising a total of 510 diabetes patients, of whom only 5% had T1D. Due to the small number of T1D patients involved, no interpretation could be drawn from this group. As patients with T1D have a significantly increased long-term risk of death after CABG compared with patients with T2D (6), and patients without diabetes and with T2D have a similar long-term risk of death after CABG (2,6), there is a

**TABLE 3 Absolute Risks of Death From Any Cause, MI, HF, Stroke, Repeat Revascularization, and Death From CHD in Patients With T1D Who Underwent PCI or CABG From 1995-2013 in Sweden**

Outcome	1-Yr Rate		2-Yr Rate		5-Yr Rate	
	CABG	PCI	CABG	PCI	CABG	PCI
Death	5 (0.7)	93 (5.0)	8 (1.2)	155 (8.3)	44 (6.4)	347 (18.6)
MI*	7 (1.0)	135 (7.2)	15 (2.2)	189 (10.1)	48 (7.0)	302 (16.2)
HF*	31 (4.5)	155 (8.3)	42 (6.1)	215 (11.5)	75 (11.0)	341 (18.3)
Stroke	16 (2.3)	64 (3.4)	22 (3.2)	105 (5.6)	47 (6.9)	158 (8.5)
Repeat revascularization†	20 (2.9)	673 (36)	32 (4.7)	737 (39.6)	61 (8.9)	816 (43.8)
Death from CHD	3 (0.4)	68 (3.7)	6 (0.9)	103 (5.5)	25 (3.7)	199 (10.7)

Values are number of events (%). \*Follow-up started 31 days after revascularization for MI and HF failure hospitalization. †Follow-up started 8 days after the index revascularization.  
Abbreviations as in Tables 1 and 2.

**CENTRAL ILLUSTRATION** Revascularization in Patients With Type 1 Diabetes: All-Cause Mortality



Nyström, T. et al. *J Am Coll Cardiol.* 2017;70(12):1441-51.

This figure shows the cumulative all-cause mortality, estimated with the Kaplan-Meier method, in type 1 diabetes patients with multivessel disease who underwent revascularization by coronary artery bypass grafting (CABG) (n = 683) or percutaneous coronary intervention (PCI) (n = 1,863) from 1995 to 2013 in Sweden.


knowledge gap regarding strategies for multivessel revascularization in patients with T1D.

In the present study, we found increased coronary heart disease mortality in the PCI group. This finding was first reported in the BARI study, which enrolled patients between 1988 and 1991 (1). Similarly, patients treated with PCI in the FREEDOM study (2), which was conducted more than 10 years after the BARI study (1), had increased all-cause mortality. Similar to the findings in our study, in the subgroup analyses of patients with diabetes in the SYNTAX study, there was a trend towards an increased all-cause mortality, and a significantly increased cardiac-specific mortality in patients who underwent PCI compared to those who underwent CABG (2). We found the largest differences in risk between CABG- and PCI-treated patients for myocardial infarction and repeat revascularization. In the FREEDOM study, a similar association was found, with more than

double the rate of myocardial infarction in the PCI group 5 years after randomization (2).

The FREEDOM study, which included patients between 2005 and 2010, reported 5-year event rates similar to those in our study for all outcomes, except for a higher rate of death. This may partly be related to an older study population included in the FREEDOM study (2). In the current study, the 30-day risk of stroke was higher in the CABG group, with event rates similar to those in the FREEDOM study, but the absolute risk was small, and the difference between patients treated with PCI and those treated with CABG had disappeared after 2 years of follow-up. Furthermore, in the BARI 2D study, patients with T2D were randomized to medical treatment or revascularization in 2 groups: one where patients were treated with PCI, and the other where they were treated with CABG (14). Revascularization was not associated with reduced mortality

**FIGURE 2** Outcomes in Relation to Revascularization Strategy



This figure shows the cumulative incidence, estimated with the Kaplan-Meier method, of (A) coronary heart disease (CHD) mortality, (B) acute myocardial infarction (AMI), (C) heart failure (HF), (D) stroke, and (E) repeat revascularization during follow-up in T1D patients treated with PCI or CABG. Follow-up started at the time of revascularization for death and stroke, at 31 days after the intervention for myocardial infarction and heart failure, and 8 days after the intervention for repeat revascularization. Abbreviations as in Figure 1.

in either group, but patients who underwent CABG had a significantly reduced risk of major cardiovascular events compared with patients who were treated only with medical therapy during follow-up. There was no difference in major cardiovascular events in patients treated with PCI compared with those treated medically.

Patients with diabetes have an accelerated atherothrombosis (15) with an early onset of atherosclerosis, suggested to be more diffuse, more extensively involved, and with more distal coronary lesions compared with patients without diabetes (16). Therefore, the target vessel for a bypass graft in patients with diabetes is often in an inferior condition compared with the target vessel from patients without diabetes. Despite this, cardiovascular complications differ between T1D and T2D, not only in that T1D presents at younger age, but also in that women are affected to the same degree and at the same age as men (7). Also, poor glycemic control before CABG is associated with increased risk of death in patients with T1D (17), an association that is not as pronounced in patients with T2D (18). Previous studies have demonstrated that both glycemic control and insulin treatment are predictors of long-term outcomes after CABG (19-21). Recently, it was demonstrated, in a substudy of the FREEDOM study, that the clinical event rate was higher in patients with diabetes treated with insulin compared to those without insulin treatment; however, no interaction was demonstrated between groups, suggesting that insulin treatment in itself is not a risk factor for the prognosis in patients with diabetes undergoing PCI or CABG (22). In the current study, patients who underwent PCI were older, were more often female, had a longer duration of diabetes, lower GFR, and were more likely to have heart failure, active cancer, end-stage renal disease, and prior stroke compared with patients who underwent CABG. After adjustment for these and a number of other differences, there was still an excess risk and rate of coronary heart disease mortality, myocardial infarction, and repeat revascularization in patients with T1D who underwent PCI compared with those who underwent CABG.

Based on data from the BARI study, the National Heart, Lung, and Blood Institute released a clinical alert in 1995 recommending CABG as the preferred method for multivessel revascularization in patients with diabetes. However, this alert had no measurable effect on the choice of revascularization method for patients with diabetes in the United States (23). Thereafter, results from both the FREEDOM and SYNTAX studies confirmed the early findings from the BARI study, leading to strong recommendations,

in both Europe and the United States, to use CABG over PCI for multivessel revascularization in patients with diabetes (4,5). In the present study, more patients with T1D underwent CABG than PCI each year from 1995 to 1999. Thereafter, there was a steady decline in number of CABGs performed. From 2008 to 2013, the preferred strategy for multivessel revascularization was CABG in only 24 patients compared with PCI in 655 patients. The reason why guideline recommendations were not followed, and PCI was chosen over CABG to such a large extent in our observational study, remains elusive.

**STUDY LIMITATIONS.** The main limitation was the large differences in risks of outcomes during the first year of follow-up. This indicates that there was significant confounding by indication present, meaning that some patients who underwent PCI did so because they were too sick to undergo CABG. Indeed, there were major differences in patient characteristics between the 2 groups, with more patients with prior stroke, heart failure, active cancer, and end-stage renal disease, all strong predictors of early and late outcomes after cardiac revascularization, in the PCI group. Moreover, there was also most likely unmeasured confounders present that we had no information about, such as frailty, which might have been a reason to choose PCI over CABG. In addition, the vast majority of patients who underwent CABG had their procedures performed within the first few years of the study period. This may explain some of the differences in patient characteristics, between groups. However, by using inverse probability of treatment weighting based on propensity scores, we adjusted for these differences, but cannot exclude that there was residual confounding present, even after adjustment. We had no information about cardiovascular medications aimed at secondary prevention. This most likely diluted the finding of an increased risk associated with PCI treatment compared with CABG treatment because secondary prevention became more aggressive during the study period, specifically in diabetes patients. Moreover, we had no information on the types of stents used, which varied between bare-metal stents and different types of drug-eluting stents due to the long study period. However, in previous studies, the benefit of CABG over PCI in patients with diabetes has been independent of whether bare-metal stents (1), or drug-eluting stents (2,3) have been used. Another limitation was that we were not able to adjust for changes in the epidemiology of coronary heart disease, with a significantly reduced incidence of myocardial infarction and reduced long-term mortality following myocardial infarction during the

study period (24). As CABG was the preferred method for multivessel revascularization during the early years of the study period, with higher risks associated with coronary heart disease, we believe that this may have, if anything, diluted our findings. The largest differences in risk were found for repeat revascularization, and myocardial infarction, which is related to the completeness of revascularization among PCI patients (25). These differences may have been attenuated if we would have been able to adjust for complete or incomplete revascularization in the PCI group (25). As our study was an observational cohort study, the results may not be completely comparable to the findings in the BARI, FREEDOM, or SYNTAX studies, where patients with diabetes were randomized to treatment with either PCI or CABG (1-3).

The main strength of our study was the size of this unique study population of T1D patients and the large number of events, with 1,195 deaths, and 726 myocardial infarctions during a mean follow-up of more than 10 years. This allowed us to report risks for each outcome separately, and with high precision in our estimates. We used high-quality national health care registers to obtain information, all of which were previously evaluated and found to have high validity (8-10). The Patient and the Cause-of-Death register used to retrieve outcomes has complete coverage of the country, and therefore we had no loss to follow-up.

## CONCLUSIONS

Notwithstanding the inclusion of patients who might not have been able to undergo CABG in the

PCI group, in this nationwide cohort of T1D patients with multivessel coronary artery disease, we found that CABG was associated with a lower risk of coronary heart disease mortality, myocardial infarction, and repeat revascularization compared with PCI. Even if our findings indicate that CABG should be the preferred strategy for multivessel revascularization in patients with T1D, our findings should be interpreted with some caution because of the observational nature of the study, and maybe more importantly, the large differences in risks in the first year of follow-up, indicating that there were large inherent differences in risk at baseline between the PCI and CABG groups.

**ADDRESS FOR CORRESPONDENCE:** Dr. Martin J. Holzmann, Functional Area of Emergency Medicine, C1:63, Karolinska University Hospital, Huddinge, Stockholm 14186, Sweden. E-mail: [martin.holzmann@sil.se](mailto:martin.holzmann@sil.se).

## PERSPECTIVES

**COMPETENCY IN PATIENT CARE:** Patients with T1D and multivessel coronary artery disease in need of revascularization benefit more from CABG compared with PCI.

**TRANSLATIONAL OUTLOOK:** More work is needed to improve clinical implementation of recommendations favoring surgical over percutaneous revascularization in patients with T1D as well as T2D.

## REFERENCES

1. BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1997;96:1761-9.
2. Farkouh ME, Domanski M, Sleeper LA, et al. FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;367:2375-84.
3. Kappetein AP, Head SJ, Morice MC, et al. SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg* 2013;43:1006-13.
4. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35:2541-619.
5. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2014;64:1929-49.
6. Holzmann MJ, Rathsman B, Eliasson B, et al. Long-term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. *J Am Coll Cardiol* 2015;65:1644-52.
7. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. *Diabetes Care* 2014;37:2843-63.
8. Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). *Heart* 2010;96:1617-21.
9. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). *Diabetes Care* 2010;33:1640-6.
10. Ludvigsson JF, Andersson E, Ekblom A, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health* 2011;11:450.
11. Barbondes SH, Haywood PL. Comparison of developmentally regulated lectins from three

species of cellular slime mold. *Biochim Biophys Acta* 1979;550:297-308.

12. Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. *N Engl J Med* 2017;376:1407-18.

13. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010;55:432-40.

14. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360:2503-15.

15. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. *Eur Heart J* 2011;32:2748-57.

16. Pajunen P, Taskinen MR, Nieminen MS, Syväne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. *Am J Cardiol* 2000;86:1080-5.

17. Nyström T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. *J Am Coll Cardiol* 2015;66:535-43.

18. Kuhl J, Sartipy U, Eliasson B, Nyström T, Holzmann MJ. Relationship between preoperative

hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. *Int J Cardiol* 2016; 202:291-6.

19. Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in coronary artery bypass patients improves outcomes and decreases recurrent ischemic events. *Circ* 2004;109:1497-502.

20. Whang W, Bigger JT Jr., CABG Patch Trial Investigators and Coordinators. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from the CABG Patch Trial database. *J Am Coll Cardiol* 2000;36:1166-72.

21. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. *J Am Coll Cardiol* 2002;40: 418-23.

22. Dangas GD, Farkouh ME, Sleeper LA, et al., FREEDOM Investigators. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. *J Am Coll Cardiol* 2014;64:1189-97.

23. McGuire DK, Anstrom KJ, Peterson ED. Influence of the Angioplasty Revascularization Investigation National Heart, Lung, and

Blood Institute Diabetic Clinical Alert on practice patterns: results from the National Cardiovascular Network Database. *Circulation* 2003;107:1864-70.

24. Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. *BMC Cardiovasc Disord* 2017;17:53.

25. Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. *N Engl J Med* 2015;372:1213-22.

---

**KEY WORDS** coronary artery disease, myocardial revascularization, prognosis, Sweden

---

**APPENDIX** For expanded Methods and References sections as well as supplemental figures and tables, please see the online version of this article.



Go to <http://www.acc.org/jacc-journals-cme> to take the CME/MOC quiz for this article.